Literature DB >> 33766816

The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer.

Hiroyuki Arai1, Andrew Elliott2, Joanne Xiu2, Jingyuan Wang1, Francesca Battaglin1, Natsuko Kawanishi1, Shivani Soni1, Wu Zhang1, Joshua Millstein3, Davendra Sohal4, Richard M Goldberg5, Michael J Hall6, Aaron J Scott7, Moh'd Khushman8, Jimmy J Hwang9, Emil Lou10, Benjamin A Weinberg11, John L Marshall11, Albert C Lockhart12, Phillip Stafford13, Jian Zhang13, Roberto Moretto14, Chiara Cremolini15, W Michael Korn16, Heinz-Josef Lenz17.   

Abstract

PURPOSE: Defective DNA damage response (DDR) is a hallmark of cancer leading to genomic instability and is associated with chemosensitivity. Although the mismatch repair system has been extensively studied, the clinical implications of other mechanisms associated with DDR alterations in patients with colorectal cancer remain unclear. This study aimed to understand DDR pathways alterations and their association with common clinical features in patients with colorectal cancer. EXPERIMENTAL
DESIGN: Next-generation sequencing and whole-transcriptome sequencing were conducted using formalin-fixed paraffin-embedded samples submitted to a commercial Clinical Laboratory Improvement Amendments-certified laboratory. Samples with pathogenic or presumed pathogenic mutations in 29 specific DDR-related genes were considered as DDR-mutant (DDR-MT) and the remaining samples as DDR-wild type (DDR-WT).
RESULTS: Of 9,321 patients with colorectal cancer, 1,290 (13.8%) were DDR-MT. The frequency of DDR-MT was significantly higher in microsatellite instability-high (MSI-H) cases than in microsatellite stable cases (76.4% vs. 9.5%). The DDR-MT genotype was higher in the right-sided, RAS-wild, BRAF-mutant, and CMS1 subgroups. However, these associations were primarily confounded by the distribution of MSI status. Compared with the DDR-WT tumors, the DDR-MT tumors had a higher mutational burden and gene expression levels in the immune-related pathway, which were independent of MSI status.
CONCLUSIONS: We characterized a distinct subgroup of patients with colorectal cancer with tumors harboring mutations in the DDR-related genes. These patients more commonly had MSI-H tumors and exhibited an activated immune signature regardless of their tumor's MSI status. These findings warrant further investigations to develop personalized treatment strategies in this significant subgroup of patients with colorectal cancer. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 33766816     DOI: 10.1158/1078-0432.CCR-20-3635

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

1.  Are Homologous Recombination Deficiency Mutations Relevant in Colorectal Cancer?

Authors:  Michael S Lee; Scott Kopetz
Journal:  J Natl Cancer Inst       Date:  2022-02-07       Impact factor: 11.816

2.  Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.

Authors:  Roberto Moretto; Andrew Elliott; Jian Zhang; Hiroyuki Arai; Marco Maria Germani; Veronica Conca; Joanne Xiu; Phillip Stafford; Matthew Oberley; Jim Abraham; David Spetzler; Daniele Rossini; Carlotta Antoniotti; John Marshall; Anthony Shields; Gilberto Lopes; Sara Lonardi; Filippo Pietrantonio; Gianluca Tomasello; Alessandro Passardi; Emiliano Tamburini; Daniele Santini; Giuseppe Aprile; Gianluca Masi; Alfredo Falcone; Heinz-Josef Lenz; Michael Korn; Chiara Cremolini
Journal:  J Natl Cancer Inst       Date:  2022-02-07       Impact factor: 11.816

3.  Comprehensive Molecular Profiling of Colorectal Cancer With Situs Inversus Totalis by Next-Generation Sequencing.

Authors:  Hongsen Li; Liu Gong; Huanqing Cheng; Huina Wang; Xiaochen Zhang; Chuangzhou Rao; Zhangfa Song; Da Wang; Haizhou Lou; Feng Lou; Shanbo Cao; Hongming Pan; Yong Fang
Journal:  Front Oncol       Date:  2022-04-20       Impact factor: 5.738

4.  Cannabidiol promotes apoptosis of osteosarcoma cells in vitro and in vivo by activating the SP1-CBX2 axis.

Authors:  Fangxing Xu; Guiyuan Sun; Zhibin Peng; Jingsong Liu; Zecheng Li; Jinglong Yan
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

5.  Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers.

Authors:  Michael Cerniglia; Joanne Xiu; Axel Grothey; Michael J Pishvaian; Yasmine Baca; Jimmy J Hwang; John L Marshall; Ari M VanderWalde; Anthony F Shields; Heinz-Josef Lenz; W Michael Korn; Mohamed Salem; Philip A Philip; Richard M Goldberg; Jia Zeng; Sunnie S Kim
Journal:  Mol Cancer Ther       Date:  2021-11-01       Impact factor: 6.009

Review 6.  Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy.

Authors:  Daniel Czajkowski; Radosław Szmyd; Harriet E Gee
Journal:  J Med Imaging Radiat Oncol       Date:  2022-04-23       Impact factor: 1.667

Review 7.  Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.

Authors:  Fabio Catalano; Roberto Borea; Silvia Puglisi; Andrea Boutros; Annalice Gandini; Malvina Cremante; Valentino Martelli; Stefania Sciallero; Alberto Puccini
Journal:  Cancers (Basel)       Date:  2022-03-09       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.